☆ 4.5 Article

Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis

ADVANCES IN THERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model

Drew MacCannell et al.

Summary: This study investigated the dosing regimens for the fastest restoration of steady-state concentrations of nusinersen in the cerebrospinal fluid (CSF) after a treatment interruption during maintenance dosing. The results showed that two doses of nusinersen at 14-day intervals are optimal for treatment interruptions of >= 8 to < 16 months since the last dose, while three doses at 14-day intervals are optimal for treatment interruptions of >= 16 to < 40 months. Interruptions of >= 40 months require the full loading regimen to rapidly restore nusinersen levels in CSF.

CNS DRUGS (2022)

添加到收藏夹

Article Economics

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom

Siu Hing Lo et al.

Summary: The study found that patients and caregivers prioritize improved motor and breathing function, preferring oral treatment. Disutilities were substantial for SMA disease outcomes and care aspects, illustrating the importance of motor and breathing function in treatment decisions.

PHARMACOECONOMICS (2022)

添加到收藏夹

Article Clinical Neurology

Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study

Juan F. Vazquez-Costa et al.

Summary: The study assessed the safety and efficacy of nusinersen in adult SMA patients, finding significant improvements in multiple motor scales in the treated group, with most patients experiencing some degree of improvement with treatment. However, the most severely affected patients with complex spines may have a less favorable risk-benefit ratio.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data

Judit Erdos et al.

Summary: This systematic review aimed to evaluate the mid-and long-term effectiveness of approved drugs or combination therapies in different types of spinal muscular atrophy (SMA) patients. The results showed that Nusinersen, onasemnogene abeparvovec, and combination therapies improved motor function in SMA type 1 patients, while SMA type 2 to type 4 patients treated with Nusinersen showed stability or slight improvement. However, there were limited reports on quality of life measures, and the mid-and long-term effectiveness of Risdiplam could not be determined.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study

Lauren Elman et al.

Summary: Limited evidence exists on real-world adherence to nusinersen for the treatment of spinal muscular atrophy (SMA). Data from a multi-site retrospective chart review of 86 adults with SMA showed that 92% of the patients remained on nusinersen during the study, and the majority of patients followed the dosing schedule as prescribed.

JOURNAL OF NEUROMUSCULAR DISEASES (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis

Marjolaine Gauthier-Loiselle et al.

Summary: The study found that adherence to nusinersen was not ideal in real-world usage, and non-adherence and discontinuation were associated with more comorbidities, higher healthcare resource utilization, and increased costs for patients.

ADVANCES IN THERAPY (2021)

添加到收藏夹

Article Genetics & Heredity

Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment

Alisha Monnette et al.

Summary: The study found that patients and caregivers in SMA treatment prioritize attributes such as improvements in motor and breathing function, broad indication, oral or one-time infusion administration, and minimal risk. Some patients are willing to trade off additional gains in efficacy for a change in route of administration.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen

Drew MacCannell et al.

Summary: The study elucidated the impact of dosing delays on cerebrospinal fluid concentrations of nusinersen in the treatment of spinal muscular atrophy, emphasizing the importance of promptly resuming the original dosing schedule for maintaining therapeutic efficacy.

NEUROMUSCULAR DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Nusinersen Treatment in Adults With Spinal Muscular Atrophy

Tina Duong et al.

Summary: This study evaluated changes in motor and respiratory function in adults with spinal muscular atrophy (SMA) following treatment with nusinersen over a two-year period. The results showed significant improvements in various motor and respiratory measures in participants, suggesting the efficacy of nusinersen in treating SMA. All participants tolerated nusinersen well with no significant adverse events reported.

NEUROLOGY-CLINICAL PRACTICE (2021)

添加到收藏夹

Article Pediatrics

Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience

Moran Lavie et al.

Summary: The study reported respiratory outcomes of 20 SMA1 patients treated with Nusinersen in real-world settings. Most patients remained stable in their need for respiratory support, but some experienced acute respiratory failure leading to death or severe brain injury.

PEDIATRIC PULMONOLOGY (2021)

添加到收藏夹

Article Economics

Economic burden of spinal muscular atrophy in the United States: a contemporary assessment

Marcus Droege et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

New treatments in spinal muscular atrophy: an overview of currently available data

Sithara Ramdas et al.

EXPERT OPINION ON PHARMACOTHERAPY (2020)

添加到收藏夹

Article Clinical Neurology

Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study

Tim Hagenacker et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Pediatrics

Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy

Ali Jalali et al.

JOURNAL OF PEDIATRICS (2020)

添加到收藏夹

Article Orthopedics

Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion

Luca Labianca et al.

JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Combined Effect of Income and Medication Adherence on Mortality in Newly Treated Hypertension: Nationwide Study of 16 Million Person-Years

Hokyou Lee et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)

添加到收藏夹

Article Clinical Neurology

A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy

Carla D. Zingariello et al.

NEUROLOGY-CLINICAL PRACTICE (2019)

添加到收藏夹

Review Medicine, General & Internal

Medication adherence influencing factors-an (updated) overview of systematic reviews

Alina Gast et al.

SYSTEMATIC REVIEWS (2019)

添加到收藏夹

Article Clinical Neurology

Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges

Jonathan Yong et al.

JOURNAL OF NEUROMUSCULAR DISEASES (2019)

添加到收藏夹

Article Clinical Neurology

Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

Richard S. Finkel et al.

NEUROMUSCULAR DISORDERS (2018)

添加到收藏夹

Article Clinical Neurology

Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

Eugenio Mercuri et al.

NEUROMUSCULAR DISORDERS (2018)

添加到收藏夹

Article Medicine, General & Internal

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

E. Mercuri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Pediatrics

Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy

Alyssa M. Burgart et al.

JAMA PEDIATRICS (2018)

添加到收藏夹

Article Clinical Neurology

Evidence in focus: Nusinersen use in spinal muscular atrophy Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

David Michelson et al.

NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

A multi-source approach to determine SMA incidence and research ready population

Ingrid E. C. Verhaart et al.

JOURNAL OF NEUROLOGY (2017)

添加到收藏夹

Review Clinical Neurology

Spinal muscular atrophy: A changing phenotype beyond the clinical trials

Eduardo F. Tizzano et al.

NEUROMUSCULAR DISORDERS (2017)

添加到收藏夹

Article Genetics & Heredity

Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States

Cathy Lally et al.

ORPHANET JOURNAL OF RARE DISEASES (2017)

添加到收藏夹

Article Genetics & Heredity

Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review

Ingrid E. C. Verhaart et al.

ORPHANET JOURNAL OF RARE DISEASES (2017)

添加到收藏夹

Article Clinical Neurology

Natural history of infantile-onset spinal muscular atrophy

Stephen J. Kolb et al.

ANNALS OF NEUROLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience

Manon Hache et al.

JOURNAL OF CHILD NEUROLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States

Craig I. Coleman et al.

PLOS ONE (2016)

添加到收藏夹

Review Clinical Neurology

The Genetics of Spinal Muscular Atrophy: Progress and Challenges

Michelle A. Farrar et al.

NEUROTHERAPEUTICS (2015)

添加到收藏夹

Review Clinical Neurology

Childhood spinal muscular atrophy: controversies and challenges

Eugenio Mercuri et al.

LANCET NEUROLOGY (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.